Two cases of aggressive clear cell renal cell carcinoma in patients with suspected VHL disease deviated from the traditionally indolent course, 'underscoring the heterogeneity of tumour biology' and 'highlight the limitations of strict size-based management.'
Key Findings
Results
A middle-aged male with suspected VHL disease presented with bilateral renal tumours accompanied by inferior vena cava tumour thrombus and synchronous liver metastases.
The patient underwent right radical nephrectomy with thrombectomy and contralateral partial nephrectomy.
This presentation deviated from the traditionally indolent course expected in VHL-associated RCC.
The case demonstrates that VHL-associated RCC can present with advanced vascular and distant metastatic involvement.
Results
A young male with suspected VHL disease presented with a large unilateral renal mass showing sarcomatoid and rhabdoid differentiation, classified as WHO/ISUP grade 4 and staged pT3a.
The tumor demonstrated sarcomatoid and rhabdoid differentiation, features associated with aggressive biological behavior.
The tumor was staged pT3a, indicating locally advanced disease.
WHO/ISUP grade 4 represents the highest pathological grade, consistent with aggressive ccRCC.
This presentation is atypical for VHL-associated RCC, which is traditionally considered more indolent than sporadic RCC.
Background
Both cases highlight limitations of the '3 cm rule' that has traditionally guided nephron-sparing interventions in VHL disease management.
The '3 cm rule' is based on the principle that tumours smaller than 3 cm rarely metastasise in VHL disease.
Accumulating evidence suggests this paradigm 'is not universal, with some VHL-associated RCCs demonstrating aggressive biological behaviour despite their small size.'
Both reported cases deviated from the expected indolent course, suggesting size alone is insufficient to guide management decisions.
The authors emphasize 'the importance of vigilant surveillance, histopathological assessment and early genetic evaluation.'
Discussion
VHL-associated clear cell RCC demonstrates biological heterogeneity that challenges the assumption of uniformly indolent behavior in this hereditary syndrome.
VHL disease is described as 'a hereditary cancer syndrome predisposing to renal cell carcinoma (RCC), typically considered more indolent than sporadic RCC.'
The two cases presented with aggressive features including metastatic disease, vascular invasion, and high-grade histology.
The authors conclude that 'recognition of aggressive variants is essential to optimise surgical planning and multidisciplinary management in VHL patients.'
Both cases involved suspected rather than confirmed genetically proven VHL disease, based on the abstract's language.
What This Means
This research describes two unusual cases of kidney cancer in patients suspected to have Von Hippel-Lindau (VHL) disease, a hereditary condition that typically causes kidney tumors considered less dangerous than non-inherited kidney cancers. Doctors managing VHL disease have long followed a 'watch and wait' approach for tumors smaller than 3 centimeters, based on the observation that small VHL-associated tumors almost never spread to other parts of the body. However, both patients in this report showed signs of aggressive disease: one had cancer that had already spread to his liver and invaded a major blood vessel, while the other had a large tumor with cellular features (sarcomatoid and rhabdoid differentiation) that are strongly associated with rapid growth and poor outcomes.
This research suggests that not all VHL-associated kidney cancers follow the expected slow-growing, non-spreading pattern. Some tumors in VHL patients can behave aggressively regardless of their size or the usual assumptions about hereditary kidney cancer. The authors argue that relying solely on tumor size to decide when and how to treat VHL patients may be insufficient, and that careful microscopic examination of tumor tissue and genetic testing should be incorporated into patient care plans.
For people with VHL disease and their medical teams, this research suggests that regular and thorough surveillance is important, and that any VHL-associated kidney tumor — not just larger ones — warrants careful evaluation. A team-based approach involving urologists, oncologists, radiologists, and genetic specialists may be needed to catch and manage aggressive tumors early in this population.
Bharti N, Sureka S, Singh U, Gupta O, Rao R. (2026). Unexpected aggressiveness in VHL-associated clear cell renal cell carcinoma: insights from two patients highlighting biological heterogeneity.. BMJ case reports. https://doi.org/10.1136/bcr-2025-270527